Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Public ClinicalTrials.gov record NCT05166889. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (OBERON)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior to enrolment.
Study identification
- NCT ID
- NCT05166889
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,132 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 3, 2022 (Actual)
- Primary completion
- Jan 19, 2026 (Actual)
- Completion
- Mar 11, 2026 (Actual)
- Last update posted
- Apr 16, 2026
2022 – 2026
United States locations
- U.S. sites
- 36
- U.S. states
- 23
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Huntsville | Alabama | 35801 | — |
| Research Site | Mobile | Alabama | 36608 | — |
| Research Site | Montgomery | Alabama | 36106 | — |
| Research Site | Phoenix | Arizona | 85044 | — |
| Research Site | Bakersfield | California | 93301 | — |
| Research Site | Sacramento | California | 95821 | — |
| Research Site | Boynton Beach | Florida | 33435 | — |
| Research Site | Ormond Beach | Florida | 32174 | — |
| Research Site | Plantation | Florida | 33324 | — |
| Research Site | Meridian | Idaho | 83642 | — |
| Research Site | Evergreen Park | Illinois | 60805 | — |
| Research Site | Normal | Illinois | 61761 | — |
| Research Site | Iowa City | Iowa | 52242 | — |
| Research Site | Kansas City | Kansas | 66104 | — |
| Research Site | Baton Rouge | Louisiana | 70816 | — |
| Research Site | Zachary | Louisiana | 70791 | — |
| Research Site | Baltimore | Maryland | 21224 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Missoula | Montana | 59808 | — |
| Research Site | Brick | New Jersey | 08724 | — |
| Research Site | New York | New York | 10037 | — |
| Research Site | The Bronx | New York | 10455 | — |
| Research Site | Charlotte | North Carolina | 28277 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Gastonia | North Carolina | 28054 | — |
| Research Site | Fargo | North Dakota | 58104 | — |
| Research Site | DuBois | Pennsylvania | 15801 | — |
| Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Research Site | Sayre | Pennsylvania | 18840 | — |
| Research Site | Rapid City | South Dakota | 57702 | — |
| Research Site | Franklin | Tennessee | 37067 | — |
| Research Site | Houston | Texas | 77022 | — |
| Research Site | Kingwood | Texas | 77339 | — |
| Research Site | Salt Lake City | Utah | 84108 | — |
| Research Site | Burlington | Vermont | 05401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 176 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05166889, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05166889 live on ClinicalTrials.gov.